Vinorelbine News and Research

RSS
Vinorelbine is an anticancer drug that belongs to the family of plant drugs called vinca alkaloids.
Research focuses on optimization of solid lipid nanoparticle that encapsulates Vinorelbine bitartrate

Research focuses on optimization of solid lipid nanoparticle that encapsulates Vinorelbine bitartrate

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Trial shows PARP inhibitor as novel treatment option for patients with advanced breast cancers

Trial shows PARP inhibitor as novel treatment option for patients with advanced breast cancers

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations

PARP inhibitor can be new treatment option for patients with metastatic breast cancer, BRCA mutations

Targeted therapy appears to be more effective in preventing lung cancer recurrence

Targeted therapy appears to be more effective in preventing lung cancer recurrence

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

Eli Lilly to present Phase III PROCLAIM trial results at ASCO Annual Meeting

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

Accelerated treatment regimen feasible for advanced NSCLC

Accelerated treatment regimen feasible for advanced NSCLC

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

Adjuvant chemotherapy and adjuvant radiation recommended for R1 resected cancer patients

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Study examines whether eribulin offers added benefit to women with breast cancer

Study examines whether eribulin offers added benefit to women with breast cancer